BOCA RATON, Fla., July 12, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced a strategic agreement focused on marketing the SRT-100 Vision™ with SkinCure Oncology, a leading turnkey provider of IGSRT solutions in the dermatology industry. SkinCure uses the same quality and safety features of leading cancer center models for the delivery of Sensus’ most technically advanced and innovative device to date, the SRT-100 Vision, to dermatology practices.
“Sensus’ strategic relationship with SkinCure Oncology is representative of our customer-centric approach in supporting the dermatology community, not to mention a valuable resource to further expand our market position,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We look forward to continue working in lock-step with the SkinCure team, a proven partner of Sensus, to lead the industry and provide the most effective IGSRT solution available to patients in need all over the country.”
The SRT-100 Vision is built with all of the same features and efficacy of the SRT-100 and delivers precise, calibrated doses of SRT, while also offering high-frequency ultrasound for imaging. The SRT-100 Vision allows for basal and squamous cell carcinomas, as well as keloid tissue, to be assessed more thoroughly and treatment to be more precisely targeted.
When the ultrasound is placed over the treatment area using the laser positioning system, doctors can assess the lesion to see how deep it is and fine-tune the exact amount of radiation that is needed. The device also allows physicians to better assess how the lesion is progressing with each treatment session, while recording each session for the patient’s records via the LesionCam.
“We entered into this agreement with Sensus based on our belief in its technology and market lead in IGSRT delivery systems,” added Kerwin Brandt, CEO, Skincure Oncology. “Our unique delivery model provides the capital, human resources and expertise, thereby allowing dermatology practices to deliver daily cutting-edge IGSRT treatments to patients. Through the SkinCure solution, we provide the Sensus SRT-100 Vision unit and suite buildout, address state regulatory requirements and give access to radiation oncologists for consultation and full-time board-certified radiation therapists to deliver treatments. We provide a patient-focused solution that continues to deliver excellent clinical outcomes – all of the while minimizing headaches for clinicians.”
About SkinCure Oncology
SkinCure Oncology is a national turnkey provider of Image-Guided SRT solutions in the Dermatology space. Its founders bring extensive experience in Radiation Oncology, business development, and the Dermatology industry. It has partnered with Dermatology practices from New York to California, and, continues to enjoy its market leading position in the delivery of IGSRT. For more information, visit https://www.skincureoncology.com.
About Sensus Healthcare
Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.
For more information, visit https://sensus.ericchesbrough.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: our ability to achieve and sustain profitability; market acceptance of the SRT-100 product line; our ability to successfully commercialize our products, including the SRT-100; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future, as well as complying with the restrictions our existing revolving credit facility imposes; our ability to expand, manage and maintain our direct sales and marketing organizations; our actual financial results may vary significantly from forecasts and from period to period; our ability to successfully develop new products, improve or enhance existing products or acquire complementary products, technologies, services or businesses; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, including the SRT-100, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; market risks regarding consolidation in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our reliance on third party manufacturers and sole- or single-source suppliers; our ability to reduce the per unit manufacturing cost of the SRT-100; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; off label use of our products; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; limited trading in our shares and the concentration of ownership of our shares; cyberattacks and other data breaches and the adverse effect on our reputation; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; the provisions in our certificate of incorporation, bylaws, or Delaware law that discourage takeovers or that limit certain disputes to be brought exclusively in the Delaware Court of Chancery; geographic concentration of our customers in the U.S. and China; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Media Contacts:
Caitlin Kasunich / Kathryne Hunter
KCSA Strategic Communications
212-896-1241 / 212-896-1204
[email protected] / [email protected]
Investor Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
[email protected]
View original content:https://www.prnewswire.com/news-releases/sensus-healthcare-announces-strategic-agreement-with-skincure-oncology-300679979.html
SOURCE Sensus Healthcare, Inc.
